Necroptosis-Related LncRNAs Signature and Subtypes for Predicting Prognosis and Revealing the Immune Microenvironment in Breast Cancer.
breast cancer
immune infiltration
immunotherapy
long non-coding RNAs
necroptosis
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
01
03
2022
accepted:
15
04
2022
entrez:
10
6
2022
pubmed:
11
6
2022
medline:
11
6
2022
Statut:
epublish
Résumé
Necroptosis is a mode of programmed cell death that overcomes apoptotic resistance. We aimed to construct a steady necroptosis-related signature and identify subtypes for prognostic and immunotherapy sensitivity prediction. Necroptosis-related prognostic lncRNAs were selected by co-expression analysis, and were used to construct a linear stepwise regression model We constructed a robust necroptosis-related 22-lncRNA model, serving as an independent prognostic factor for breast cancer (BRCA). The low-risk group seemed to be the immune-activated type. Meanwhile, it showed that the higher the tumor mutation burden (TMB), the higher the riskScore. PD-L1-CTLA4 combined immunotherapy seemed to be a promising treatment strategy. Lastly, patients were assigned to 4 clusters to better discern the heterogeneity among patients. The necroptosis-related lncRNA signature and molecular clusters indicated superior predictive performance in prognosis and the immune microenvironment, which may also provide guidance to drug regimens for immunotherapy and provide novel insights into precision medicine.
Identifiants
pubmed: 35686108
doi: 10.3389/fonc.2022.887318
pmc: PMC9171493
doi:
Types de publication
Journal Article
Langues
eng
Pagination
887318Informations de copyright
Copyright © 2022 Xu, Zheng, Zhou, Ye, Xu and Meng.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Biol Proced Online. 2021 Dec 15;23(1):24
pubmed: 34906078
Nat Immunol. 2017 Aug 22;18(9):962-972
pubmed: 28829444
Front Cell Dev Biol. 2021 Sep 20;9:736298
pubmed: 34616742
Mol Biol Rep. 2021 Dec;48(12):8075-8095
pubmed: 34671902
J Oncol. 2022 Mar 18;2022:8909631
pubmed: 35342420
Transl Oncol. 2021 Jan;14(1):100957
pubmed: 33246289
Signal Transduct Target Ther. 2020 Sep 4;5(1):182
pubmed: 32883946
J Oncol. 2021 Nov 08;2021:6718443
pubmed: 34790235
Chin Med J (Engl). 2020 Apr 5;133(7):853-862
pubmed: 32106121
JAMA Dermatol. 2021 Nov 01;157(11):1306-1315
pubmed: 34643650
Science. 2018 Feb 16;359(6377):801-806
pubmed: 29301960
Cell. 2013 Jul 3;154(1):26-46
pubmed: 23827673
Front Immunol. 2021 Nov 25;12:706936
pubmed: 34899682
Crit Rev Oncog. 2013;18(1-2):43-73
pubmed: 23237552
Bioinformatics. 2006 Jan 1;22(1):58-67
pubmed: 16257984
Lancet. 2020 Dec 5;396(10265):1817-1828
pubmed: 33278935
Biochim Biophys Acta. 2016 Jan;1859(1):169-76
pubmed: 26149773
Cancer Biomark. 2022;34(3):393-401
pubmed: 35068448
Future Oncol. 2020 Aug;16(24):1801-1813
pubmed: 32633563
Bioinformatics. 2010 Jun 15;26(12):1572-3
pubmed: 20427518
Front Oncol. 2021 Dec 13;11:807410
pubmed: 34966691
J Immunol Res. 2021 Jan 7;2021:6668573
pubmed: 33506060
Immunity. 2014 Oct 16;41(4):567-78
pubmed: 25367573
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Nature. 2015 Jan 15;517(7534):311-20
pubmed: 25592536
Oncol Rep. 2021 Jan;45(1):5-12
pubmed: 33416128
Nature. 2000 Aug 17;406(6797):747-52
pubmed: 10963602
J Oncol. 2022 Jan 19;2022:4566577
pubmed: 35096059
PPAR Res. 2021 Dec 30;2021:7056506
pubmed: 35027921
N Engl J Med. 2020 Jun 25;382(26):e108
pubmed: 32579834
Ann Oncol. 2020 May;31(5):569-581
pubmed: 32278621
Genes (Basel). 2022 Feb 14;13(2):
pubmed: 35205391
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Nat Med. 2018 May;24(5):541-550
pubmed: 29686425
Front Oncol. 2021 Sep 23;11:582664
pubmed: 34631507
Front Cell Dev Biol. 2021 Dec 16;9:799507
pubmed: 34977039
PeerJ. 2022 Mar 24;10:e13057
pubmed: 35356464
Int J Gen Med. 2021 Nov 16;14:8249-8262
pubmed: 34815698
Front Oncol. 2021 Oct 28;11:756225
pubmed: 34778071
Cell. 2019 Nov 14;179(5):1033-1055
pubmed: 31730848
Front Oncol. 2021 Nov 15;11:766248
pubmed: 34868991
Front Cell Dev Biol. 2021 Dec 02;9:736682
pubmed: 34926441
Cancers (Basel). 2021 Feb 21;13(4):
pubmed: 33670082
Cancer Discov. 2021 Feb;11(2):266-281
pubmed: 33451983
Front Genet. 2021 Sep 06;12:726387
pubmed: 34552622
Front Med (Lausanne). 2021 Dec 23;8:757432
pubmed: 35004726
J Natl Compr Canc Netw. 2018 Oct;16(10):1259-1268
pubmed: 30323094
Cancers (Basel). 2021 Nov 25;13(23):
pubmed: 34885027
Signal Transduct Target Ther. 2021 Dec 20;6(1):422
pubmed: 34924561
Ann Oncol. 2019 Mar 1;30(3):405-411
pubmed: 30475947
J Cell Sci. 2012 Dec 1;125(Pt 23):5591-6
pubmed: 23420197
PeerJ. 2021 Nov 23;9:e12383
pubmed: 34900411
Life Sci. 2020 Oct 15;259:118297
pubmed: 32822718
J Biol Chem. 2017 Jul 28;292(30):12375-12382
pubmed: 28615453
Mol Cancer. 2019 May 23;18(1):100
pubmed: 31122251
Curr Opin Cell Biol. 2010 Apr;22(2):263-8
pubmed: 20045303